Current Treatment of Advanced
Non-Small Cell Lung Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the webinars held June 8, 2016 and June 22, 2016.  If you participated in the live webinars, you are not eligible for continuing education credits from this archive.

This activity is valid from August 25, 2016 to December 31, 2018

Instructions for CME/CNE: Listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

These presentations require Adobe Flash Player.  You can download it here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from Lilly, USA LLC.




NSCLC is often diagnosed at an advanced stage, and despite progress in early detection and treatment, prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include agents such as pemetrexed, gemcitabine, bevacizumab, erlotinib, docetaxel, and cetuximab. Additionally, new options have become available for patients with metastatic squamous NSCLC. The concept of tailoring therapies based on clinical and molecular markers has transformed the management of NSCLC.

Guidelines from the National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) have recently been updated to incorporate a section on maintenance therapy in the management of advanced NSCLC. Maintenance therapy refers to treatment that prevents a cancer from spreading after it has responded to initial treatments, which has been shown to extend the lives of advanced NSCLC patients.

Upon Completion of this activity, participants will be able to:

  • Review the mechanisms of action, safety and efficacy of current and emerging treatments in the management of advanced NSCLC

  • Analyze recent clinical data and pathological evidence on novel treatments for patients with metastatic squamous NSCLC

  • Describe current data relating histology and biomarkers to treatment decisions and subtyping in advanced NSCLC

  • Evaluate new treatment options for patients who have metastatic NSCLC with disease progression

  • Examine patient and clinical factors used to guide first-line and maintenance therapy selection in NSCLC

  • Discuss whether switching treatment or continued use of the same treatment is most appropriate in maintenance or progressive settings of advanced NSCLC

Faculty: Thomas Stinchcombe, MD
Clinical Assistant Professor, Clinical Research
UNC Lineberg Comprehensive Cancer Center


Dr. Stinchcombe has served on advisory boards/panels for Boehringer Ingelheim, Bristol-Myers Squibb and Celgene. He has received research grant from Bristol-Myers Squibb, EMD Serono and Genentech. His presentation is being peer reviewed for potential bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jacquelyn Smith, RN, BSN, MA, CMCN has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Centerís Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by an educational grant from Lilly, USA LLC.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.